文献速递抗栓抗凝管理治疗药物监测与药物基因组学

体外循环期间影响普通肝素药代与药效的因素

Factors Influencing Unfractionated Heparin Pharmacokinetics and Pharmacodynamics During a Cardiopulmonary Bypass.
PubMed 文献 · Clin Pharmacokinet · 2024-01-02

本研究通过个体患者数据荟萃分析,整合两项单中心前瞻性观察研究,采用非线性混合效应模型构建体外循环下普通肝素的药代/药效模型,发现肝素清除受体重和肝素类型影响,分布容积受体重和术前纤维蛋白原影响,药效符合对数线性模型并受血液稀释和术前纤维蛋白原影响,模型可据此个体化给药。

要点

  • 肝素清除受体重和UFH类型影响,分布容积受体重和术前纤维蛋白原影响。
  • 药效学符合对数线性模型,血液稀释和术前纤维蛋白原影响抗凝效果。
  • 模型方程可基于目标ACT水平和患者协变量个体化UFH剂量。

核心结论

  • 群体模型有效表征了体外循环患者的UFH药代/药效特征。
  • 荟萃分析纳入新的药代/药效协变量,支持个体化给药方案。
  • 模型有潜力通过贝叶斯估计实现个体化。

研究设计与样本

  • 个体患者数据荟萃分析,整合两项单中心前瞻性观察研究。
  • 两项研究使用不同UFH类型进行抗凝。
  • 采用非线性混合效应方法构建药代/药效模型。

主要发现

  • UFH抗活化因子/抗凝血酶活性由二室模型最佳描述。
  • 肝素清除受体重和特定UFH类型影响。
  • 分布容积受体重和术前纤维蛋白原水平影响。
  • 药效数据符合对数线性模型,纳入血液稀释和术前纤维蛋白原效应。

关键数值与推荐

  • 模型推导出基于目标活化凝血时间水平和患者协变量的个体化UFH给药方程。

临床怎么用

  • 可依据目标ACT水平和患者协变量(体重、纤维蛋白原、肝素类型、血液稀释)个体化UFH剂量。
  • 模型有潜力结合贝叶斯估计用于实时个体化给药。

局限性

  • 数据来自两项单中心研究,样本来源有限。
  • 既往研究因统计效能不足未能识别较多协变量。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Unfractionated heparin (UFH) is commonly used during cardiac surgery with a cardiopulmonary bypass to prevent blood clotting. However, empirical administration of UFH leads to variable responses. Pharmacokinetic and pharmacodynamic modeling can be used to optimize UFH dosing and perform real-time individualization. In previous studies, many factors that could influence UFH pharmacokinetics/pharmacodynamics had not been taken into account such as hemodilution or the type of UFH. Few covariates were identified probably owing to a lack of statistical power. This study aims to address these limitations through a meta-analysis of individual data from two studies. METHODS: An individual patient data meta-analysis was conducted using data from two single-center prospective observational studies, where different UFH types were used for anticoagulation. A pharmacodynamic/pharmacodynamic model of UFH was developed using a non-linear mixed-effects approach. Time-varying covariates such as hemodilution and fluid infusions during a cardiopulmonary bypass were considered. RESULTS: Activities of UFH's anti-activated factor/anti-thrombin were best described by a two-compartment model. Unfractionated heparin clearance was influenced by body weight and the specific UFH type. Volume of distribution was influenced by body weight and pre-operative fibrinogen levels. Pharmacodynamic data followed a log-linear model, accounting for the effect of hemodilution and the pre-operative fibrinogen level. Equations were derived from the model to personalize UFH dosing based on the targeted activated clotting time level and patient covariates. CONCLUSIONS: The population model effectively characterized UFH's pharmacokinetics/pharmacodynamics in cardiopulmonary bypass patients. This meta-analysis incorporated new covariates related to UFH's pharmacokinetics/pharmacodynamics, enabling personalized dosing regimens. The proposed model holds potential for individualization using a Bayesian estimation.

来源:Clin Pharmacokinet,查看原文。版权归原作者所有。

引用

  1. Gibert A, Lanoiselée J, Gouin-Thibault I, et al. Factors Influencing Unfractionated Heparin Pharmacokinetics and Pharmacodynamics During a Cardiopulmonary Bypass. Clin Pharmacokinet. 2024. PMID: 38169065. doi:10.1007/s40262-023-01334-3

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。